Department of Emergency Medicine, Daegu Fatima Hospital, Daegu, Korea.
Department of Emergency Medicine, Keimyung University Graduate School, Daegu, Korea.
Korean J Intern Med. 2021 Mar;36(2):433-440. doi: 10.3904/kjim.2019.272. Epub 2020 Mar 31.
BACKGROUND/AIMS: The aim of this study was to compare antimicrobial resistance, clinical features, and outcomes of community-onset Escherichia coli (COEC) and Klebsiella pneumoniae (COKP) bacteremia.
The medical records of patients diagnosed with E. coli or K. pneumoniae bacteremia in the emergency department of a 750-bed secondary care hospital in Daegu, Korea from January 2010 to December 2016 were retrospectively reviewed.
A total of 866 patients with COEC bacteremia and 299 with COKP bacteremia were enrolled. COEC bacteremia, compared to COKP bacteremia, had higher rates of 3rd generation cephalosporin (3GC) (18.8% vs. 8.4%, p < 0.001) and f luoroquinolone (FQ) (30.4% vs. 8.0%, p < 0.001) resistance. The patients with COKP bacteremia had higher Charlson comorbidity indices (CCI) (1.8 ± 2.0 vs. 1.5 ± 1.8, p = 0.035), Pittsburgh bacteremia scores (PBS) (2.0 ± 2.6 vs. 1.3 ± 1.8, p < 0.001), and 30-day mortality (14.44% vs. 8.8%, p = 0.008) than the patients with COEC bacteremia. Age younger than 70 years, male sex, polymicrobial infections, pneumonia, intra-abdominal infection, PBS ≥ 2, and Foley catheter insertion were independent predictive factors for COKP bacteremia compared to COEC bacteremia in the multivariate analysis. CCI, PBS, and intensive care unit admission were independent risk factors for 30-day mortality in the multivariate analysis.
3GCs and FQs are still useful for the empirical treatment of patients with probable COKP bacteremia. The patients with COKP bacteremia had worse outcomes because of its greater severity and more frequent underlying comorbidities.
背景/目的:本研究旨在比较社区获得性大肠埃希菌(COEC)和肺炎克雷伯菌(COKP)菌血症的抗菌药物耐药性、临床特征和结局。
回顾性分析 2010 年 1 月至 2016 年 12 月期间韩国大邱一家 750 床位二级保健医院急诊科诊断为大肠埃希菌或肺炎克雷伯菌菌血症的患者的病历。
共纳入 866 例大肠埃希菌菌血症和 299 例肺炎克雷伯菌菌血症患者。与肺炎克雷伯菌菌血症相比,大肠埃希菌菌血症的第三代头孢菌素(3GC)(18.8% vs. 8.4%,p<0.001)和氟喹诺酮(FQ)(30.4% vs. 8.0%,p<0.001)耐药率更高。肺炎克雷伯菌菌血症患者的 Charlson 合并症指数(CCI)(1.8±2.0 vs. 1.5±1.8,p=0.035)、匹兹堡菌血症评分(PBS)(2.0±2.6 vs. 1.3±1.8,p<0.001)和 30 天死亡率(14.44% vs. 8.8%,p=0.008)均高于大肠埃希菌菌血症患者。在多变量分析中,年龄<70 岁、男性、混合感染、肺炎、腹腔内感染、PBS≥2、 Foley 导管插入是肺炎克雷伯菌菌血症而非大肠埃希菌菌血症的独立预测因素。CCI、PBS 和入住重症监护病房是多变量分析中 30 天死亡率的独立危险因素。
3GC 和 FQ 仍然是经验性治疗疑似肺炎克雷伯菌菌血症患者的有效药物。由于肺炎克雷伯菌菌血症病情更严重且常合并基础合并症,故其预后更差。